GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

“The impact on not just kidney disease but also cardiovascular disease and on all-cause death.” Ozempic and other semaglutide ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...